These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 24057092)

  • 1. Clinical efficacy of abatacept compared to adalimumab and tocilizumab in rheumatoid arthritis patients with high disease activity.
    Takahashi N; Kojima T; Kaneko A; Kida D; Hirano Y; Fujibayashi T; Yabe Y; Takagi H; Oguchi T; Miyake H; Kato T; Fukaya N; Ishikawa H; Hayashi M; Tsuboi S; Kanayama Y; Kato D; Funahashi K; Matsubara H; Hattori Y; Hanabayashi M; Hirabara S; Terabe K; Yoshioka Y; Ishiguro N
    Clin Rheumatol; 2014 Jan; 33(1):39-47. PubMed ID: 24057092
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial.
    Schiff M; Weinblatt ME; Valente R; van der Heijde D; Citera G; Elegbe A; Maldonado M; Fleischmann R
    Ann Rheum Dis; 2014 Jan; 73(1):86-94. PubMed ID: 23962455
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of abatacept and tocilizumab in patients with rheumatoid arthritis treated in clinical practice: results from the nationwide Danish DANBIO registry.
    Leffers HC; Ostergaard M; Glintborg B; Krogh NS; Foged H; Tarp U; Lorenzen T; Hansen A; Hansen MS; Jacobsen MS; Dreyer L; Hetland ML;
    Ann Rheum Dis; 2011 Jul; 70(7):1216-22. PubMed ID: 21551512
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictive factors for achieving low disease activity at 52 weeks after switching from tumor necrosis factor inhibitors to abatacept: results from a multicenter observational cohort study of Japanese patients.
    Kojima T; Takahashi N; Kaneko A; Kida D; Hirano Y; Fujibayashi T; Yabe Y; Takagi H; Oguchi T; Miyake H; Kato T; Watanabe T; Hayashi M; Shioura T; Kanayama Y; Funahashi K; Asai S; Yoshioka Y; Terabe K; Takemoto T; Asai N; Ishiguro N
    Clin Rheumatol; 2016 Jan; 35(1):219-25. PubMed ID: 26631102
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: findings of a phase IIIb, multinational, prospective, randomized study.
    Weinblatt ME; Schiff M; Valente R; van der Heijde D; Citera G; Zhao C; Maldonado M; Fleischmann R
    Arthritis Rheum; 2013 Jan; 65(1):28-38. PubMed ID: 23169319
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical, functional and radiographic consequences of achieving stable low disease activity and remission with adalimumab plus methotrexate or methotrexate alone in early rheumatoid arthritis: 26-week results from the randomised, controlled OPTIMA study.
    Kavanaugh A; Fleischmann RM; Emery P; Kupper H; Redden L; Guerette B; Santra S; Smolen JS
    Ann Rheum Dis; 2013 Jan; 72(1):64-71. PubMed ID: 22562973
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative efficacy of biologics as monotherapy and in combination with methotrexate on patient reported outcomes (PROs) in rheumatoid arthritis patients with an inadequate response to conventional DMARDs--a systematic review and network meta-analysis.
    Jansen JP; Buckley F; Dejonckheere F; Ogale S
    Health Qual Life Outcomes; 2014 Jul; 12():102. PubMed ID: 24988902
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Generalized estimating equation model to compare drug effects on synovitis of the dominant wrist in severe rheumatoid arthritis between tocilizumab versus adalimumab versus abatacept using high-resolution ultrasound.
    Chen YC; Chiu WC; Su FM; Chen JF
    Int J Rheum Dis; 2018 Sep; 21(9):1695-1700. PubMed ID: 29024421
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the clinical effectiveness of tumour necrosis factor inhibitors and abatacept after insufficient response to tocilizumab in patients with rheumatoid arthritis.
    Akiyama M; Kaneko Y; Kondo H; Takeuchi T
    Clin Rheumatol; 2016 Nov; 35(11):2829-2834. PubMed ID: 26971256
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Longterm efficacy and safety of abatacept in patients with rheumatoid arthritis treated in routine clinical practice: effect of concomitant methotrexate after 24 weeks.
    Takahashi N; Kojima T; Kaneko A; Kida D; Hirano Y; Fujibayashi T; Yabe Y; Takagi H; Oguchi T; Miyake H; Kato T; Watanabe T; Hayashi M; Kanayama Y; Funahashi K; Asai S; Yoshioka Y; Takemoto T; Terabe K; Asai N; Ishiguro N
    J Rheumatol; 2015 May; 42(5):786-93. PubMed ID: 25834204
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Abatacept with methotrexate versus other biologic agents in treatment of patients with active rheumatoid arthritis despite methotrexate: a network meta-analysis.
    Guyot P; Taylor P; Christensen R; Pericleous L; Poncet C; Lebmeier M; Drost P; Bergman G
    Arthritis Res Ther; 2011; 13(6):R204. PubMed ID: 22151924
    [TBL] [Abstract][Full Text] [Related]  

  • 12. No predictive effect of body mass index on clinical response in patients with rheumatoid arthritis after 24 weeks of biological disease-modifying antirheumatic drugs: a single-center study.
    Kim SK; Choe JY; Park SH; Lee H
    Clin Rheumatol; 2016 May; 35(5):1129-36. PubMed ID: 26932795
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the efficacies of abatacept and tocilizumab in patients with rheumatoid arthritis by propensity score matching.
    Kubo S; Nakayamada S; Nakano K; Hirata S; Fukuyo S; Miyagawa I; Hanami K; Saito K; Tanaka Y
    Ann Rheum Dis; 2016 Jul; 75(7):1321-7. PubMed ID: 26245754
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-world experience of tocilizumab in rheumatoid arthritis: sub-analysis of data from the Italian biologics' register GISEA.
    Iannone F; Ferraccioli G; Sinigaglia L; Favalli EG; Sarzi-Puttini P; Atzeni F; Gorla R; Bazzani C; Govoni M; Farina I; Gremese E; Carletto A; Giollo A; Galeazzi M; Foti R; Bianchino L; La Grasta L; Lapadula G
    Clin Rheumatol; 2018 Feb; 37(2):315-321. PubMed ID: 28980085
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative efficacy of tocilizumab, abatacept and rituximab after non-TNF inhibitor failure: results from a multicentre study.
    Pascart T; Philippe P; Drumez E; Deprez X; Cortet B; Duhamel A; Houvenagel E; Flipo RM
    Int J Rheum Dis; 2016 Nov; 19(11):1093-1102. PubMed ID: 27018857
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biologics or tofacitinib for people with rheumatoid arthritis naive to methotrexate: a systematic review and network meta-analysis.
    Singh JA; Hossain A; Mudano AS; Tanjong Ghogomu E; Suarez-Almazor ME; Buchbinder R; Maxwell LJ; Tugwell P; Wells GA
    Cochrane Database Syst Rev; 2017 May; 5(5):CD012657. PubMed ID: 28481462
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical efficacy of abatacept in Japanese rheumatoid arthritis patients.
    Takahashi N; Kojima T; Terabe K; Kaneko A; Kida D; Hirano Y; Fujibayashi T; Yabe Y; Takagi H; Oguchi T; Miyake H; Kato T; Fukaya N; Ishikawa H; Hayashi M; Tsuboi S; Kato D; Funahashi K; Matsubara H; Hattori Y; Hanabayashi M; Hirabara S; Yoshioka Y; Ishiguro N
    Mod Rheumatol; 2013 Sep; 23(5):904-12. PubMed ID: 22975734
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of a 12-week observational period for predicting low disease activity at 52 weeks in RA patients treated with abatacept: a retrospective observational study based on data from a Japanese multicentre registry study.
    Takahashi N; Kojima T; Kaneko A; Kida D; Hirano Y; Fujibayashi T; Yabe Y; Takagi H; Oguchi T; Miyake H; Kato T; Fukaya N; Hayashi M; Tsuboi S; Kanayama Y; Funahashi K; Hanabayashi M; Hirabara S; Asai S; Yoshioka Y; Ishiguro N
    Rheumatology (Oxford); 2015 May; 54(5):854-9. PubMed ID: 25339638
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative effectiveness of biologics in patients with rheumatoid arthritis stratified by body mass index: a cohort study in a Swiss registry.
    Vallejo-Yagüe E; Burkard T; Finckh A; Burden AM;
    BMJ Open; 2024 Feb; 14(2):e074864. PubMed ID: 38331859
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Description of the efficacy and safety of three new biologics in the treatment of rheumatoid arthritis.
    Storage SS; Agrawal H; Furst DE
    Korean J Intern Med; 2010 Mar; 25(1):1-17. PubMed ID: 20195397
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.